Promising new Vaccine Offers Dual Protection Against Typhoid and Salmonella Infections
Table of Contents
A novel vaccine demonstrating strong potential to combat both typhoid fever and non-typhoidal Salmonella infections has successfully completed a Phase 1 clinical trial. Teh investigational Trivalent Salmonella Conjugate vaccine (TSCV), developed by researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health, represents a critically important step forward in addressing these widespread and frequently enough deadly illnesses.
The vaccine’s innovative design utilizes sugar molecules derived from salmonella Typhi, the bacterium responsible for typhoid fever, alongside those from two prevalent serotypes of invasive non-typhoidal Salmonella enterica.These sugar molecules are linked to proteins, a technique designed to amplify the body’s immune recognition and response.
Addressing a Major public Health Threat
Salmonella infections pose a significant health burden globally. The U.S. Centers for disease Control and Prevention (CDC) estimates that Salmonella causes 1.35 million infections and over 26,000 hospitalizations annually within the United States. Crucially, the S. enterica serotypes targeted by TSCV are frequently linked to outbreaks in the U.S. stemming from contaminated poultry, eggs, and produce, highlighting the vaccine’s potential impact on domestic food safety.
However, the need for this vaccine is most acute in regions like sub-Saharan Africa, where the impact of these diseases is devastating. In 2017 alone, the region experienced over 420,000 cases of salmonellosis, resulting in 66,000 deaths, primarily among children. Typhoid fever contributed an additional 650,000 cases and nearly 9,000 deaths. A single vaccine offering protection against both diseases could dramatically improve public health outcomes for vulnerable populations.
Phase 1 Trial Results Demonstrate Safety and Efficacy
The randomized, placebo-controlled trial involved 22 healthy adults who received either a low dose (6.25 micrograms) or a high dose (12.5 micrograms) of TSCV,or a placebo. The vaccine proved to be well-tolerated, with participants reporting only mild discomfort at the injection site. Importantly, all vaccinated participants exhibited strong immune responses to all three targeted Salmonella strains, a result not observed in the placebo group.
Researchers also noted that some participants displayed pre-existing Salmonella antibodies, suggesting prior exposure through foodborne sources. this prior exposure may actually enhance the vaccine-induced immunity, a promising observation for broader vaccine effectiveness. Moreover, the vaccine triggered a robust immune response involving white blood cells that help clear infections-an effect previously unseen with one of the vaccine’s protein components. these findings suggest the potential for both localized and systemic protection against Salmonella.
Building on Existing Technology and Future Development
The TSCV vaccine was developed in collaboration with Bharat biotech International Limited and leverages the World Health Organization (WHO)-prequalified Typbar TCV platform, providing a strong foundation for further development. Researchers are now planning to advance to additional trials, with a particular focus on studies involving young children – the demographic most susceptible to typhoid and non-typhoidal S. enterica infections.
The results of this pivotal Phase 1 trial have been published in the prestigious journal Nature Medicine. Wilbur Chen, M.D., M.S., Professor of Medicine at the University of Maryland School of Medicine and Chief of the Adult Clinical Studies section within the Center for Vaccine Development, served as the study’s first and corresponding author. This new vaccine represents a beacon of hope in the ongoing fight against these preventable, yet pervasive, infectious diseases.
